文献速递治疗药物监测与药物基因组学特殊人群用药

唾液作为新生儿庆大霉素治疗药物监测采样基质的可行性与群体药代动力学模拟研究

Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study.
PubMed 文献 · Br J Clin Pharmacol · 2021-11-07

本研究为多中心前瞻性观察队列,纳入54例接受静脉庆大霉素的新生儿,用LC-MS/MS测定唾液庆大霉素浓度并建立群体PK模型,蒙特卡洛模拟(虚拟队列n=3000)比较唾液与血浆TDM的目标达成概率。结果显示唾液TDM可行,四份唾液样本的准确率为81%,血浆两份和一份样本分别为94%和87%,精度差异可能无临床相关性,尤其对早产儿。

要点

  • 唾液TDM四样本准确率81%,血浆两样本94%、单样本87%。
  • 唾液与血浆TDM精度差异可能无临床相关性,早产儿尤甚。
  • 唾液采样为非侵入性,可作为新生儿庆大霉素TDM的可行替代。

核心结论

  • 唾液用于新生儿庆大霉素TDM是可行的,其与血浆TDM的精度差异可能无临床相关性,尤其对早产儿。

研究设计与样本

  • 多中心前瞻性观察队列研究,纳入54例接受静脉庆大霉素的新生儿,每人最多采集8份唾液样本。
  • 用LC-MS/MS测定唾液庆大霉素浓度,以NONMEM建立群体PK模型描述唾液与血浆浓度关系。
  • 蒙特卡洛模拟采用代表性虚拟队列(n=3000)评估唾液与血浆TDM的目标达成概率。

主要发现

  • 血浆PK可用既往已发表模型充分描述,模型追加唾液隔室,一级输入速率常数k13为0.023 h⁻¹,一级消除速率常数k30为0.169 h⁻¹。
  • k30的个体间变异为38%,月经后年龄(PMA)与k13和k30均呈负相关。
  • 模拟显示四份唾液样本TDM在81%的模拟病例中准确,两份血浆样本为94%,一份血浆样本为87%。

临床怎么用

  • 对新生儿庆大霉素TDM,可考虑用唾液替代血浆采样以减少侵入性操作,尤其适用于早产儿。
  • 采用唾液TDM时需采集四份样本,并注意其准确率(81%)低于两份血浆样本(94%)。

局限性

  • 研究样本量为54例新生儿,模拟虚拟队列n=3000,结论需更大规模临床验证。
  • 唾液与血浆TDM的精度差异是否真正无临床相关性,尚需进一步临床结局研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Therapeutic drug monitoring (TDM) of gentamicin in neonates is recommended for safe and effective dosing and is currently performed by plasma sampling, which is an invasive and painful procedure. In this study, feasibility of a non-invasive gentamicin TDM strategy using saliva was investigated. METHODS: This was a multicentre, prospective, observational cohort study including 54 neonates. Any neonate treated with intravenous gentamicin was eligible for the study. Up to eight saliva samples were collected per patient at different time-points. Gentamicin levels in saliva were determined with liquid chromatography tandem mass-spectrometry (LC-MS/MS). A population pharmacokinetic (PK) model was developed using nonlinear mixed-effects modelling (NONMEM) to describe the relation between gentamicin concentrations in saliva and plasma. Monte Carlo simulations with a representative virtual cohort (n = 3000) were performed to evaluate the probability of target attainment with saliva versus plasma TDM. RESULTS: Plasma PK was adequately described with an earlier published model. An additional saliva compartment describing the salivary gentamicin concentrations was appended to the model with first-order input (k13 0.023 h-1 ) and first-order elimination (k30 0.169 h-1 ). Inter-individual variability of k30 was 38%. Postmenstrual age (PMA) correlated negatively with both k13 and k30 . Simulations demonstrated that TDM with four saliva samples was accurate in 81% of the simulated cases versus 94% when performed with two plasma samples and 87% when performed with one plasma sample. CONCLUSION: TDM of gentamicin using saliva is feasible and the difference in precision between saliva and plasma TDM may not be clinically relevant, especially for premature neonates.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Samb A, Kruizinga M, Tallahi Y, et al. Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study. Br J Clin Pharmacol. 2021. PMID: 34625981. doi:10.1111/bcp.15105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。